AMGN · News · 20260914N

IMDELLTRA Pipeline Progress

AMGEN INC · 2026-09-14 · Importance 31 · Surprise 42

The FDA approved an update to IMDELLTRA (tarlatamab-dlle) prescribing information that substantially reduces the recommended monitoring time for the first two doses. The change is intended to support broader access to treatment in community healthcare settings. IMDELLTRA is indicated for people with extensive-stage small cell lung cancer, potentially making administration more convenient for eligible patients and providers.

Key facts

• The regulatory update to reduce monitoring time for the first two doses of Imdelltra "aims to streamline the administration process for patients receiving the treatment." source